NovaBridge to present expanded Phase 1b givastomig combo data in first-line metastatic gastroesophageal cancer at ESMO 2026

• NovaBridge Biosciences scheduled expanded Phase 1b data for givastomig with nivolumab and mFOLFOX at ESMO 2026.
• Results will be presented October 25 in Madrid, offering a more mature read on safety, activity, and durability.
• Study targets first-line, HER2-negative, CLDN18.2-positive, PD-L1-positive metastatic or unresectable gastroesophageal adenocarcinoma.
• Program supports a shift toward registrational development, with a global randomized Phase 2 trial already underway.
• FDA granted Fast Track status for the combination in previously untreated advanced or metastatic gastroesophageal adenocarcinoma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081605PRIMZONEFULLFEED9842393) on October 08, 2026, and is solely responsible for the information contained therein.